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Abstract:  
Objective: To identify, review and critically appraise model-based economic evaluations of all 
types of interventions for people with dementia and their carers.  
Design: A systematic literature search was undertaken to identify model-based evaluations 
of dementia interventions. A critical appraisal of included studies was carried out using 
guidance on good practice methods for decision-analytic models in health technology 
assessment, with a focus on model structure, data, and model consistency.  
Setting: Interventions for people with dementia and their carers, across prevention, 
diagnostic, treatment and disease management. 
Results: We identified 67 studies, with 43 evaluating pharmacological products, 19 covering 
prevention or diagnostic strategies, and five studies reporting non-pharmacological 
interventions. The majority of studies use Markov models with a simple structure to represent 
dementia symptoms and disease progression. Half of all studies reported taking a societal 
perspective, with the other half adopting a third-party payer perspective. Most studies follow 
good practices in modelling, particularly related to the decision problem description, 
perspective, model structure and data inputs. Many studies perform poorly in areas related to 
reporting of pre-modelling analyses, justifying data inputs, evaluating data quality, considering 
alternative modelling options, validating models and assessing uncertainty.  
Conclusions: There is a growing literature on model-based evaluations of interventions for 
dementia. The literature predominantly reports on pharmaceutical interventions for 
Alzheimer’s disease, but there is a growing literature for dementia prevention and non-
pharmacological interventions. Our findings demonstrate that decision-makers need to 
critically appraise and understand the model-based evaluations and their limitations to ensure 
they are used, interpreted and applied appropriately. 
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1 Introduction   
Economic considerations play an important role in financing and service provision for the 
diagnosis of dementia, and the treatment and care available for people with dementia. 
Economic evidence is presented in many formats, including cost of illness studies, within-trial 
cost effectiveness analyses, and model-based economic evaluations. We focus here on the 
latter and the use of decision-analytic models to assess the cost effectiveness of interventions 
for dementia. The use of model-based evaluations is attractive in a health policy context as it 
provides an explicit framework to systematically synthesise evidence available from multiple 
sources, and to estimate and compare longer term outcomes (e.g. life-expectancy, quality 
adjusted life years) and inputs (costs) for alternative interventions and/or treatment pathways. 
Model-based economic evaluations are commonly used to support decision-makers in a 
health policy context, where assessment of effectiveness and cost effectiveness in a policy-
relevant context is required.   
The usefulness and validity of the evidence available from model-based evaluations is 
dependent on the methods and data used to estimate and report the expected costs, 
outcomes and cost effectiveness of interventions. Decision-makers must assess the quality of 
the model-based evaluations and be familiar with the pros and cons of the evaluations when 
interpreting findings and using them to inform health policy. There is a growing literature on 
the use of decision-analytic models in the dementia context, including a number of high-quality 
systematic reviews. While each of the available reviews has focused on a distinctive segment 
of the care continuum, i.e. diagnosis (Handels et al., 2014), pharmacological treatment (Cohen 
and Neumann, 2008; Green, 2007; Green et al., 2011; Gustavsson et al., 2009; Hernandez et 
al., 2016; Oremus, 2008), non-pharmacological treatment (Jones et al., 2012) and 
interventions for dementia carers (Sopina and Sørensen, 2018), they shared similar objectives 
and a number of common themes. A majority of reviews aimed to understand the analytical 
approaches used to evaluate cost effectiveness through providing a detailed description of 
study characteristics, methodologies, model elements and main findings. Common findings 
across reviews have been that (i) many studies failed to present sufficient information to fully 
assess methodologies used, thus increasing the uncertainty surrounding the interpretation 
and generalisation of the results, (ii) considerable variation exists in methodological 
assumptions applied and target populations among studies, preventing a meaningful 
comparison of cost effectiveness results, and (iii) evaluations should use better quality and 
up-to-date data, particularly outcome data that better reflect the breadth of dementia 
symptoms. Prior reviews have taken a varied approach to the critical appraisal and 
assessment of methods, with few providing a comprehensive quality assessment of modelling 
methods and reporting practices against published decision-analytic models in dementia.  
None of the prior reviews have reported across the full continuum of dementia care, from 
prevention, screening, early detection and diagnosis, to treatment and care programs for 
people with dementia and their carers.   
In the current review we present a comprehensive overview of contemporary model-based 
economic evaluations of dementia interventions. We systematically review the literature 
reporting decision-analytic models used in economic evaluation of interventions for people 
with dementia and their carers (informal and family carers) across prevention, early detection, 
diagnosis and treatment and care strategies, including all types of dementia. Additionally, we 
critically assess the modelling methods used and reporting quality against good practice 
guidance on methods for decision-analytic modelling in health technology assessment, across 
key domains of model structure, data, and model consistency.  
2 Methods  
2.1 The systematic search and review of the literature  
We have undertaken the systematic review in line with the Preferred Reporting Items for 
Systematic Review and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). The 
systematic review was registered in PROSPERO international prospective register of 
systematic reviews (ID: 42017059154) in April 2017. The search strategy and keywords are 
presented in Table A1.1 (Appendix 1, published as supplementary material online attached to 
the electronic version of this paper at https://www.cambridge.org/core/journals/international-
psychogeriatrics). The search was applied to literature available up to February 2018, in the 
electronic databases of MEDLINE, CINAHL, Cochrane Library, Embase, PsycINFO, Econlit, 
HTA database, CEA registry and PubMed. Reference lists of identified publications were 
checked for additional articles meeting the inclusion criteria.  
Inclusion criteria (Table A1.2, Appendix 1) were (i) evaluations of interventions for people with 
dementia and/or their carers, covering surveillance, screening, early diagnosis, treatment, 
management and care, where (ii) economic evaluation used a decision-analytic model-based 
framework. The identification of studies was undertaken by two independent reviewers, who 
initially screened the titles and abstracts for eligibility. A study was included if both reviewers 
agreed that it met all the inclusion criteria. Dissimilarities in reviewers’ conclusion were 
resolved by discussion and/or examining the full article. Full texts of all included studies were 
reviewed independently by both reviewers. Resulting citations and reference lists in these 
reviewed studies, studies that published systematic reviews and meta-analyses were 
examined to ensure that no eligible studies were missed. Both reviewers systematically and 
independently documented the properties of the included studies.   
2.2 Quality assessment of decision-analytic models  
For quality assessment of included studies, we used the framework for assessment of good 
practice in decision-analytic models in a health technology assessment context, presented by 
Philips et al., (2006), (hereafter, referred to as the Philips checklist). The checklist is a broad 
framework which assesses three key dimensions of modelling: structure, data (including 
uncertainty) and consistency. It includes 58 items; with 9 distinct areas for model structure (23 
items), 11 areas for data (30 items), and 2 areas for model consistency (5 items). See Table 
A1.3 (Appendix 1) for detail on the Philips checklist. This checklist was used because of its 
relevance to the HTA context (Philips et al., 2004), and as it is considered to be consistent 
with the ISPOR principles of good practice for decision-analytic modelling for health care 
evaluation (Caro et al., 2012; Weinstein et al., 2003).  
The quality assessment using the Philips checklist was conducted by two independent 
reviewers. Differences between the two reviewers’ responses for each item were resolved by 
discussion and/or consultation with a third reviewer. We followed the questions and examples 
presented in Philips et al., (2004, 2006) to score a response for each item (Y=Yes, N=No, 
U=Unsure, NA=Not Applicable). The scoring decisions for a study were also influenced by the 
available literature up to that point in time, particularly with respect to other published models, 
data sources, and best practice guidelines. The standards for assessment of uncertainty 
increased over time as the number of published studies using competing models increased. 
For instance, the lack of discussion on alternative models was not heavily penalised prior to 
2000 (before the good practice guidelines released and widely adopted in the mid-2000s) 
while studies published from late 2000s required more comprehensive assessment of 
uncertainty. 
Many model-based evaluations of pharmacological treatments for Alzheimer’s disease (AD) 
have been subject to critical appraisal in the prior review by Green (2007) which reviewed 
literature reported up to 2005.  For this reason, and for pragmatic reasons, we use this prior 
review as a point of departure and limit the quality assessment of studies in this category to 
those published from 2005 onwards. All studies identified on prevention, diagnosis, and non-
pharmacological interventions are subject to quality assessment in the current review.  
3 Results  
3.1 Basic properties of studies included in the systematic review  
We identified 67 studies that met the inclusion criteria (evaluating a dementia intervention 
using decision-analytic model/s). See Figure A2.1 (Appendix 2, published as supplementary 
material online attached to the electronic version of this paper at 
https://www.cambridge.org/core/journals/international-psychogeriatrics) for detail on 
screening, identification and selection of studies and Tables A2.1 (Appendix 2) for basic 
characteristics of the studies identified by intervention type, target population, types of 
decision-analytic models and their major features.  
Two thirds of identified studies (42/67) were published after 2005 (see Figures 1 and A2.2, 
Appendix 2). All but three studies (Fuh and Wang, 2008; Hu et al., 2015; Yang and Chen, 
2016) were conducted in OECD countries. More than half of the studies had some degree of 
industry involvement (e.g. authors received direct funding from industry or were affiliated with 
industry-funded projects or groups); ten studies did not declare any information about industry 
involvement.   
INSERT FIGURE 1 
In terms of the perspective/s stated and employed in included studies, in many cases the 
perspective is dictated by the research context (and decision problem) being addressed. For 
example, specific reimbursement-setting studies commonly follow recommendations, or 
reference case methods, for regulatory agencies, for government subsidy or insurance 
approval. Approximately 40% of studies applied a societal perspective, in which both (formal) 
health and care service costs and the opportunity cost of informal care (provided by family 
carers) were accounted for, and another 40% used a narrower health system perspective 
(including Third Party Payer, Department of Health). A small number of studies (10/67) used 
more than one perspective, often the combination of societal and health system (Figure 1). 
Evaluations of pharmacological treatments accounted for 43 of the 67 included studies. A 
majority of studies (40/43) assessed the three cholinesterase inhibitors (donepezil, 
galantamine and rivastigmine) and a receptor antagonist (memantine), which have 
demonstrated modest effectiveness for the symptomatic treatment of Alzheimer's disease 
(Birks, 2006). Three studies evaluated tacrine (Henke and Burchmore, 1997), olanpazine 
(Kirbach et al., 2008) and an immunotherapy (Aβ42) (Yang and Chen, 2016). In the majority 
of these studies the decision context was treatment for people with a diagnosis of Alzheimer's 
disease (42/43); two studies covered dementia with Lewy bodies (Gustavsson et al., 2009) 
and vascular dementia (Wong et al., 2009). The main comparator in these studies was 
standard care or no treatment (35/43). None compared a pharmacological agent with a non-
pharmacological intervention.  
Two studies (2/67) evaluated a hypothetical disease modification treatment for people with 
mild cognitive impairment and pre-dementia (Budd et al., 2011; Skoldunger et al., 2013), and 
three other studies evaluated non-pharmacological interventions: a family-based program for 
mild AD (Martikainen et al., 2004), deep brain stimulation for mild AD (Mirsaeedi-Farahani et 
al., 2015) and a connected health care program for mild dementia (Dowd et al., 2018).  
We identified 19 studies evaluating strategies for prevention (Zhang et al., 2011), early 
assessment (Getsios et al., 2012; Yu et al., 2015), screening (Djalalov et al., 2012; Retchin 
and Hillner, 1994) or diagnosis of dementia (14/19). Diagnosis studies covered a large variety 
of strategies, from imaging (magnetic resonance imaging, positron emission tomography, etc.) 
to biomarker (Aβ41, cerebrospinal fluid) detection. In these studies, the main target 
populations were elderly people or those with mild cognitive impairment.  
Almost all studies used a cost utility framework (48/67), in which the primary outcome was 
quality adjusted life years, or a cost effectiveness analysis (15/67). Four studies used either 
cost benefit analysis or evaluated either outcomes or cost only. In cost effectiveness studies, 
the final outcomes were measured by clinical endpoints such as life years, the number of 
accurate diagnoses, and the number of years before full-time care or before 
institutionalisation.  
The most commonly used modelling framework was a Markov state transition model (52/67), 
followed by a decision tree approach (12/67). Four studies combined a decision-tree (for 
diagnosis) with either a Markov or a discrete event simulation model (for dementia 
progression). Six studies used a discrete event simulation (DES) framework, four of which 
were based on the model structure developed in (Getsios et al., 2010). More than two-thirds 
of all studies evaluating pharmacological treatments applied a previously published model-
based framework (see Figure 2). For instance, 16 studies adopted the model published by 
Neumann et al., (1999), and 13 studies were based on the Assessment of Health Economics 
in Alzheimer’s Disease (AHEAD) model (Caro et al., 2001). Approximately a half of studies 
(10/19) evaluating prevention, screening and diagnosis of dementia developed their own 
original models, while the rest translated previously published models into other settings. 
INSERT FIGURE 2 
Neumann et al., (1999) estimated the cost effectiveness of donepezil, compared to no 
treatment, using a Markov transition model with four health states: mild, moderate, severe and 
dead. Three AD severity states/stages were used based on the Clinical Dementia Rating 
(CDR) scale, and patients were either living in the community or in a nursing home. The 
underlying AD progression probabilities were estimated from Consortium to Establish a 
Registry for Alzheimer's Disease (CERAD) data, which is a longitudinal database of 1,145 
dementia patients in the United States between 1986 and 1995 (Morris et al., 1989). Data on 
the impact of donepezil on progression and mortality were sourced from the 24‐week 
randomized, double‐blinded, placebo-controlled clinical trial that investigated the impact of 
donepezil on patients with mild or moderate AD (Rogers et al., 1998). Subsequent studies 
applying the Neumann model kept the four-state model structures and the underlying AD 
progression while updating treatment impacts, mortality risks, costs and outcomes using the 
relevant settings. Model durations (e.g. six months, two years, 10 years to life-time) and cycle 
lengths (e.g. one month, six weeks, one year) were applied to suit the study objectives.  
The AHEAD model (Caro et al., 2001) applied a different interpretation of disease progression, 
using “need for full-time care (FTC)” as the main end-point to classify three health states: not 
requiring FTC, requiring FTC and dead. FTC was defined as the consistent requirement of 
caregiving for a significantly large amount of time per day, which was indicated by the need 
for institutional care (in a health-related facility). The likelihood of FTC at any point in time was 
estimated using patient characteristics observed in the Predictors Study Cohort of 236 patients 
with AD observed for a period of up to seven years in the United States (Stern et al., 1997). 
Patient characteristics included the (modified) Mini Mental Sate Examination (m-MMSE) 
scores, extrapyramidal signs, psychotic symptoms, disease duration and whether or not the 
patient had a young onset AD. Subsequent studies using the AHEAD model continued with 
the three-state model and its progression probabilities while revising treatment impacts, 
mortality risks, costs and outcomes. In some occasions the definition of FTC was revised to 
“institutionalisation”. The majority of these studies used a 5-year or a 10-year horizon. The 
cycle length of one month was explicitly reported in five studies (out of 13).  
A small number of alternative (dementia progression) models to AHEAD and Neumann 
incorporate more disease characteristics than just cognitive impairment. Some combinations 
of physical function (e.g. using Activities of Daily Living, instrumental Activities of Daily Living 
or Severe Impairment Battery instruments), care requirement (e.g. full-time care) and/or 
residence (community versus nursing home), or behaviour symptoms (e.g. using 
Neuropsychiatric Inventory) were used in five Markov transition models to define health states 
(nine to 12 health states), and in six DES models to initiate events and assign attributes to 
patients (see Table A2.1, Appendix 2 for more details).  
Similar to other areas of disease modelling literature, models in this dementia literature relied 
upon disease progression data estimated from observational studies, many of which date from 
the 1980s and 1990s (such as CERAD, Kungsholmen or Predictors Study Cohort). Mortality 
risks were often assumed either constant over time in studies published in the early half of the 
literature, or age- and gender-specific (based on country-specific all-cause mortality risk) in 
the recent half of the literature. In a small number of cases, a hazard ratio due to dementia 
was added to the base mortality (Budd et al., 2011; Gagnon et al., 2007; Kirbach et al., 2008; 
Lachaine et al., 2011; Lee et al., 2017; Thibault et al., 2015; Touchon et al., 2014). Impacts of 
treatment were extrapolated from short-duration clinical trials (e.g. six months) to the longer 
term (e.g. five or ten years) to fit the model duration. All studies grouped costs into the three 
main categories: intervention costs; direct medical expenditure (e.g. doctor visits, monitoring 
tests, hospitalisation); and paid (formal) care cost (e.g. community-based social and nursing 
services, nursing home fee). In cost utility analysis models, most of the studies sourced quality 
of life weights from valuation studies that used one of two generic instruments: the Health 
Utility Index (developed with a US population using HUI2, in Neumann et al., 1998 and 1999 
or a Japanese population using HUI3 in Ikeda et al., 2001) or the EuroQol, developed with a 
mostly European population (including the  UK in Jonsson et al., 2006, Spain in Lopez-Bastida 
et al., 2006, and Sweden in Ekman et al., 2007). A dementia-specific quality of life weight (e.g. 
DEMQOL developed in Rowen et al., 2012) was used in one study (Dowd et al., 2018) and 
the quality of life instrument for people with Alzheimer’s disease (QoL-AD) was used in a small 
number of studies, in which the quality of life scores were mapped into a utility scale (e.g., 
Gagnon et al., 2007; Rive et al., 2010). Out of 36 studies using a societal perspective, 32 
incorporated the informal care cost, approximated by total number of hours of caregiving and 
hourly opportunity cost, but only seven studies accounted for carers’ quality of life.   
3.2 Quality assessment of decision analytic models using the Philips checklist  
We conducted quality assessment using the Philips checklist for 55 (out of 67) studies: all 19 
studies evaluating interventions/strategies for prevention, screening, early detection and 
diagnosis of dementia; five studies evaluating non-pharmacological interventions and 
programs for people with dementia and their carers; and 31 studies (published after 2005) 
evaluating pharmacological treatments.  
Overall, “Structure” (23 items) was the area where a majority of studies scored more positively 
(“Yes”, providing sufficient details) than negatively (“No”, insufficient information or unclear 
evidence), while “Data” (30 items) and “Consistency” (5 items) showed greater limitations in 
reporting quality. It is clear that some aspects of modelling and reporting practices have 
improved overtime, evidenced by the rising percentage of items scored positively (“Yes”) in 
the Data domain over time (see Figure 3). However, information/evidence provided in certain 
domains was still inadequate to meet the checklist criteria, including comprehensive 
assessments of uncertainty (e.g. covering all four principal types of uncertainty: 
methodological; structural; heterogeneity; and parameter), validation of internal consistency 
and calibration against independent data. Only two studies scored “Yes” in more than 85% of 
all items; both of them were comprehensive (long) health technology assessment (HTA) 
reports submitted to NICE (Bond et al., 2012; Loveman et al., 2006). They both explicitly 
described a systematic approach to the literature search and thorough consideration and 
selection of models, parameters, assumptions, and pre-modelling methods, which were 
commonly omitted in other publications. We present the full quality assessment findings in 
Table A2.2 (Appendix 2), and a summary of key observations on the changes of modelling 
and reporting quality over time in Table 1.  
INSERT FIGURE 3 
INSERT TABLE 1 
Structure: Most studies clearly stated their objective and scope, the options under evaluation, 
and the analytical perspective/s and outcomes. The evidence of model types, disease states 
and pathways, evaluation horizon and cycle length were described clearly. However, those 
modelling decisions were often not accompanied by an explicit rationale and justification, such 
as why competing model structures were not considered, or why other comparator/s should 
be excluded. Studies that replicated existing models in another setting were more likely to omit 
rationale for comparators, duration and cycle length, compared to studies that developed 
original models. Unexpectedly, the latter failed to justify their (newly developed) model choices 
more often than the former (22/24 versus 22/31).  
Data: Modelling quality has improved over time. Strong improvements were observed in the 
reporting of baseline data, quality of life weights and analysis of parameter uncertainty. While 
the adoption of good modelling and reporting practices is also reflected in critical areas such 
as selecting data sources and using appropriate techniques for pre-modelling analyses, a 
majority of studies simply reported the modelling decision/approach without providing a 
rationale. For instance, while more than 80% of all studies discussed, reported and referenced 
the model data properly (items D11, D2c1, D31, D33, and D35), fewer than 20% provided 
sufficient justification for its use (items D12, D2a4, D2b2, D2b3, D2c3, D32, and D42). 
Surprisingly, only a third of studies clearly reported their systematic approach to data 
identification and selection, and 25% provided any quality assessment of the data used in their 
models (including risk of bias). With regard to uncertainty analyses, while the assessment of 
parameter uncertainty improved significantly over time (from <50% in studies published before 
2005 to >90% in those published after 2010), little improvement was observed in the 
assessment of methodological and heterogeneity uncertainties (approximately 20-25% of all 
studies).  
Consistency: This domain consists of fewer assessment items than the other domains: one 
internal and four external consistency checks. Out of 55 studies, two explicitly stated that the 
mathematical logic of their models was examined (both of them were HTA reports, Bond et 
al., 2012 for the UK and Bermingham, 2014 for Canada) and another two reported that they 
calibrated their models using external data (Gagnon et al., 2007; Gustavsson et al., 2009). All 
studies drew consistent conclusions (of cost-effectiveness) from the model results and more 
than half (32/55) compared their findings with other published models. Only a few studies 
(4/55) reported “counter-intuitive results” and attempted some explanation. Overall, we did not 
see strong evidence of improvement in the quality of modelling and reporting of evidence in 
the “Consistency” domain across the 30-year period of this literature review.  
4 Discussion  
Decision-analytic models have been used widely in the economic evaluation of dementia 
interventions in the past three decades. While this approach has been attractive in a health 
policy context, the validity of (cost-effectiveness) findings depends entirely on the modelling 
quality. That is, how well the model addresses the decision problem through modelling of 
disease progression and treatment pathways, and capturing the relevant costs and outcomes, 
and whether or not the model can be validated against external data.  
As expected, recent studies (e.g., those published after 2010) showed significant improvement 
in terms of modelling quality and reporting standard, which may be a result of  the introduction 
of guidelines on decision-analytic modelling and good practice checklists (e.g. CHEERs, 
Philips checklist). Despite this positive trend, there remain areas requiring substantial 
improvement. Some would be relatively simple, such as clear documentation of model 
characteristics (model type, number of health states, model duration, cycle length, and half-
cycle correction), data sources and assumptions underlying the model structure. Others 
require substantial improvements in modelling practice, such as a systematic approach to 
literature searches and selection of data sources and alternative models (including 
assessment of data quality), appropriate application and rationale for pre-data modelling 
methods, and comprehensive assessment of model validity and consistency using internal 
and external data sources. We acknowledge that the critical appraisal using the Philips 
checklist was a subjective process and may be more reflective of the quality of reporting than 
the quality of modelling. Studies with a higher percentage of items scored positively (“Yes”) 
did not necessarily have higher quality modelling. For instance, many items were easier to 
report and to evaluate (i.e. whether or not there was sufficient information): evaluation 
objective, target population, interventions, model type, number of health states, duration and 
cycle length. Additionally, studies that translated existing modelling frameworks into new 
settings/evaluations (with minimal revisions) could often refer to the original models (for pre-
modelling and data sources), which may have freed up space in the main text for content on 
rationale and discussion surrounding modelling methods. Our approach to critical appraisal, 
and use of the Philips checklist, does not allow a detailed assessment of the appropriateness 
of the model structure, assumptions and data sources. Nor was it possible to make meaningful 
direct comparisons of models against each other, which is only feasible through replicating 
the models used in those studies. Despite these limitations, the Philips checklist remains 
useful as a self-assessment tool for model developers to improve both modelling and reporting 
quality.  
In this review, we found the majority of models use a crude representation of dementia and 
fail to account for distinguishing features of the condition, such as behavioural and 
psychological symptoms and functional performance, all of which affect care needs and quality 
of life. This finding supports other interpretations of the literature in this field (Cohen and 
Neumann, 2008; Green et al., 2011). A few recent studies (Gagnon et al., 2007; Getsios et 
al., 2010; Hartz et al., 2012) incorporated, at least conceptually, a combination of domains to 
better reflect the impact of the underlying biological process on disease states and 
progression. Recent contributions to the modelling literature in this area, Green and Zhang 
(2016) have argued for, and provided empirical evidence to support, modelling of Alzheimer's 
disease progression using a multi-domain descriptive system, for example using cognition, 
behaviour and function as core symptom domains. Such recommendations respond to earlier 
findings in the literature on methods for model-based evaluations, and it is suggested that this 
practice becomes an integrated part of future modelling initiatives and developments for 
assessment of the progression of dementia in an HTA setting.  
While evaluation of pharmacological agents accounted for two thirds of all studies, attention 
on non-pharmacological interventions, prevention and diagnosis has been consistent over 
time, although infrequent, and possibly on the rise over recent years. The dominance of drug 
evaluation for people with AD strongly mirrors both the target population of pharmacological 
agents and the distribution pattern of dementia prevalence by types of dementia, where 
Alzheimer's disease accounts for 50%-75% of dementia cases (Prince et al., 2014). It also 
reflects the environment in which many economic evaluations are conducted: prior to approval 
of public funding for wide-scale implementation of interventions, most of which were 
pharmacological. The question remains whether or not a pharmacological-based evaluation 
model can be reapplied directly to evaluating prevention, diagnosis or non-pharmacological 
interventions. This current literature indicates that it is a reasonable approach: a half of non- 
pharmacological studies sourced their models from pharmacological evaluations. For 
instance, a prevention strategy that reduced the dementia incidence rate (Zhang et al., 2011) 
or a more precise diagnosis method that led to a higher number of patients correctly diagnosed 
at early stage (Biasutti et al., 2012; Djalalov et al., 2012; Getsios et al., 2012; Yu et al., 2015) 
or a care program (for the dementia dyads) impacting on the disease progression (Dowd et 
al., 2018; Martikainen et al., 2004) can all share a disease progression model where 
subsequent costs and QALYs are accumulated and compared. This approach can potentially 
allow for the comparison of all interventions along the continuum of dementia care from 
prevention to active disease management. It will also facilitate a better understanding of the 
impacts and potential trade-offs between interventions, thus offering decision-makers an 
opportunity to consider low-value versus high-value strategies, and the possibility of 
combining complementary therapies to suit patient settings and preferences. This is 
particularly relevant in countries where health and social services are both funded centrally 
through tax and/or social insurance and where the primary goal of HTA is ensuring efficient 
allocation of scarce resources. A caveat here is that the feasibility of this approach rests 
entirely on the quality of the core models that can successfully represent the disease 
progression patterns, capture relevant dementia symptoms and outcomes (of both person with 
dementia and their carers), and account for important disease modification factors.  
Our last observation relates to the existing capacity to perform cross (external) validation and 
convincingly draw a cost-effectiveness conclusion. It may be that cost effectiveness is 
evidenced when many studies, even when using different modelling methods, arrive at a 
similar conclusion. For instance, the cost effectiveness of memantine was established in four 
different studies/models  (Jones et al., 2004; Jonsson, 2005; Rive et al., 2010; Hu et al., 2015) 
and multiple reapplications of those models in other settings. A similar observation can be 
seen for donepezil with its economic value confirmed by at least six different studies/models, 
(Neumann et al., 1999; Jonsson et al., 1999; O’Brien et al., 1999; Teipel et al., 2007; Getsios 
et al., 2010; Peters et al., 2013). While this consistency could be interpreted as a source of 
strong evidence of external validity for those models/evaluations, it may be that the direction 
of the evidence correlates with the source of funding/sponsor. Many of these studies have 
received direct funding from industry, and in many instances may reflect the economic 
evaluation models that were likely to have been submitted by industry for subsidy 
consideration (reimbursement purposes). Studies conducted independently of industry, or for 
HTA authority, showed a less optimistic conclusion regarding the economic value of some 
interventions. This observation is supported by previous authors (Bond et al., 2012; Peters et 
al., 2013). In particular, Bond et al., (2012) stated that when using more conservative 
assumptions on elements with high uncertainty, the (estimated) incremental cost effectiveness 
ratio (using industry submission models) could be at the margins of what would normally be 
considered cost-effective. Some consideration of this issue may be useful in future research 
on the validity and consistency of results and conclusions in modelling methods.  
5 Conclusion  
We identify an expanding literature on model-based evaluations of interventions for dementia.  
The literature is predominantly reporting on pharmaceutical interventions for Alzheimer’s 
disease, but there is a growing literature for dementia prevention and non-pharmacological 
interventions. We provide a comprehensive summary and a critical review of the literature, 
finding that reporting of decision-analytic models has improved with the recent introduction of 
checklists and guidelines. However, we find some important aspects of model reporting still 
require substantial improvement, including justification of key model components and data 
selection. Findings here clearly demonstrate that decision-makers using model-based 
evaluations of dementia care need to critically appraise and understand the methods and data 
applied, and the limitations of any evaluation to ensure they are used, interpreted and applied 
appropriately.  
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